Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSelectHealth prior auth: Actimmune Akeega Coverage…
    Ask Trek AI about this page
    CurrentSelectHealthPolicy N/A

    Actimmune and Akeega prior authorization criteria

    Customize your policy alerts

    Sign up for all SelectHealth policy alerts

    Know when SelectHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements and coverage criteria for the drugs Actimmune and Akeega for SelectHealth plan members, including indications, exclusions, required documentation, and coverage duration.

    Policy Summary
    PayerSelectHealth
    PolicyCoverage criteria for Actimmune and Akeega (and related drug entries)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewNov 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for all FDA‑approved indications and provide required supporting documentation (e.g., diagnoses, prior therapy trials, two separate testosterone levels when applicable).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2drugs listed in this section
    All FDA-Approved IndicationsPA indication indicator
    Plan Yearcoverage duration
    <300 ng/dLtestosterone lab threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    11/2025
    last review

    Coverage Criteria by Medication

    inv-01: Actimmune - Initial Coverage

    Covered when ALL of the following are met

    Actimmune criteria: 1) Prior authorization is requested for an FDA‑approved indication; 2) Member has a diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis; 3) No hypersensitivity to Actimmune or E. coli‑derived products; 4) Coverage duration: Plan Year.

    inv-02: Akeega - Initial Coverage

    Covered when ALL of the following are met

    Akeega criteria: 1) Prior authorization is requested for an FDA‑approved indication; 2) Diagnosis of deleterious or suspected deleterious BRCA‑mutated metastatic castration‑resistant prostate cancer (BRCAm mCRPC); 3) Documentation of contraindication, intolerance, or failure of Lynparza; 4) Coverage duration: Plan Year.

    inv-03: Alecensa (alectinib) - Initial Coverage

    Covered when ALL of the following are met

    Alecensa coverage criteria: 1) Prior authorization is requested for an FDA‑approved indication; 2) Member has a diagnosis of non‑small cell lung cancer (NSCLC) that is ALK‑positive (documented ALK rearrangement); 3) Coverage duration: Plan Year.

    Documentation of ALK‑positive tumor required.

    inv-04: Radicava ORS (edaravone oral suspension) - Initial Coverage

    Covered when ALL of the following are met

    Radicava ORS coverage criteria: 1) Prior authorization is requested for an FDA‑approved indication; 2) Member has a diagnosis of amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria; 3) Coverage duration: Plan Year.

    Documentation of ALS per revised El Escorial criteria required.

    inv-05: ALUNBRIG (brigatinib) - Initial Coverage

    Covered when ALL of the following are met

    ALUNBRIG initial: 1) Member has a diagnosis of metastatic non‑small cell lung cancer (NSCLC); 2) Tumor is ALK‑positive; 3) Patient has failed, is intolerant to, or has a contraindication to Alecensa.

    Documentation of metastatic ALK‑positive NSCLC and prior Alecensa failure/intolerance/contraindication required.

    inv-06: Topical Testosterone - Initial Coverage

    Covered when ALL of the following are met

    Topical testosterone initial: 1) Two separate serum testosterone measurements drawn on different dates showing levels below 300 ng/dL; 2) Patient has at least ONE clinical symptom: malaise, fatigue, lethargy, muscle loss, depression, or decreased libido; 3) Indication is an FDA‑approved indication and prior authorization is requested.<300 ng/dL

    Two measurements must be on different dates; document symptom(s).

    inv-07: Testosterone therapy initial criteria

    Covered when ALL of the following are met

    Testosterone lab and symptom criteria: 1) Two separate serum testosterone measurements on different dates with serum testosterone < 300 ng/dL; 2) Documentation of at least ONE clinical symptom: malaise, fatigue, lethargy, muscle loss, depression, or decreased libido.serum testosterone < 300 ng/dL

    Both labs must be provided.

    inv-08: Prior therapy requirements

    Covered when ALL of the following are met

    Prior medication trial: 1) Previous trial on at least ONE of the following agents: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone; 2) For Major Depressive Disorder (MDD) or Schizophrenia indications, documentation of a prior trial on Rexulti is required.

    Document medication names, doses, and reasons for failure/intolerance if applicable.

    inv-09: Initial therapy - severe hypercholesterolemia

    Covered when ALL of the following are met

    LDL and triglyceride thresholds: 1) Untreated, fasting LDL cholesterol > 500 mg/dL AND triglycerides < 300 mg/dL; 2) Patient meets either genetic criteria (mutations in both alleles of LDLR or other LDLR‑affecting genes) OR family history criteria (both parents with untreated total cholesterol >250 mg/dL) AND xanthomas before age 10 as applicable; 3) Prior trial/failure/intolerance to at least one high/moderate‑intensity statin (atorvastatin, rosuvastatin, or simvastatin) or documented statin intolerance; 4) Prior trial of Repatha OR Praluent.LDL > 500 mg/dL; TG < 300 mg/dL

    Genetic/family/xanthoma criteria and prior therapy trials required as specified.

    inv-10: Initial therapy - Niemann-Pick disease type C after miglustat failure

    Covered when ALL of the following are met

    NPC after miglustat failure: 1) Patient has tried and failed at least 3 months of miglustat therapy as evidenced by lack of improvement in disease progression; 2) Patient weight >= 15 kg; 3) Genetic confirmation: mutations in both alleles of NPC1 or NPC2 OR single‑allele mutation with positive filipin staining or elevated cholestane triol/oxysterols (>2x ULN); 4) Patient presents with at least one neurological symptom (eg, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, dysphagia); 5) Patient is ambulatory (independently or with assistance); 6) SARA total score between 7 and 34 AND either gait subtest within 2–7 OR HPT‑D between 20 and 150 seconds; 7) For reauthorization, fSARA score has remained stable or improved.>= 3 months; >= 15 kg; SARA 7-34; HPT-D 20-150 sec

    All items required for initial approval; reauthorization requires stable/improved fSARA.

    inv-11: ARCALYST Coverage

    ARCALYST is covered when ALL of the following are met

    ARCALYST Coverage: 1) Diagnosis of cryopyrin‑associated periodic syndrome OR recurrent pericarditis OR deficiency of Interleukin‑1 Receptor Antagonist (DIRA); 2) Prior authorization is requested for an FDA‑approved indication; 3) ARCALYST is not used in combination with a TNF‑inhibitor.

    Coverage duration: Plan Year.

    inv-12: ADBRY / CIBINQO Coverage

    ADBRY and CIBINQO are covered when ALL of the following are met

    ADBRY/CIBINQO Initial Coverage: 1) Diagnosis of moderate to severe atopic dermatitis with body surface area >= 10%; 2) Documented failure of two prior therapies from: topical corticosteroid, topical calcineurin inhibitor, phototherapy, oral immunomodulator (azathioprine, cyclosporine, or mycophenolate), or topical PDE‑4 (Eucrisa); 3) Not used in combination with another biologic (eg, Dupixent, Xolair, Humira, Entyvio, Otezla); 4) Prior authorization is requested for an FDA‑approved indication.BSA >= 10%

    Reauthorization: for patients <100 kg who achieved clear/almost clear skin, every‑4‑week dosing should have been tried.

    inv-13: AUGTYRO - Initial Therapy

    Covered when ALL of the following are met

    AUGTYRO criteria: 1) Diagnosis of locally advanced or metastatic ROS1‑positive NSCLC OR NTRK gene fusion‑positive solid tumor; 2) Contraindication, intolerance, or prior failure of Rozlytrek; 3) Prior authorization is requested for an FDA‑approved indication.

    Coverage duration: Plan Year.

    inv-14: AUSTEDO - Initial Therapy

    Covered when ALL of the following are met

    AUSTEDO criteria: 1) Diagnosis of chorea associated with Huntington's disease OR diagnosis of tardive dyskinesia; 2) Prior authorization is requested for an FDA‑approved indication.

    Coverage duration: Plan Year.

    inv-15: Avmapki Fakzynja - Initial and Reauthorization Criteria

    Covered when ALL of the following are met

    Avmapki Fakzynja coverage criteria: 1) Diagnosis of recurrent KRAS‑mutated, recurrent low‑grade serous ovarian cancer; 2) Prior therapy including platinum‑based therapy; 3) ECOG performance status 0 or 1; 4) Patient has been treated with Mekinist or a documented medical rationale is provided explaining why Mekinist is inappropriate; 5) For reauthorization, documentation shows no disease progression per RECIST v1.1 (>=20% increase in sum of diameters).

    Initial coverage duration: 6 months.

    inv-16: Ayvakit - Covered Indications

    Covered when ANY ONE of the following documented diagnoses is present

    Ayvakit covered indications: a) Unresectable or metastatic GIST that is PDGFRA exon 18 mutation positive including PDGFRA D842V; b) Advanced Systemic Mastocytosis (ASM, SM‑AHN, or MCL); c) Indolent Systemic Mastocytosis.

    PA indicator: All FDA‑Approved Indications; molecular confirmation as required per indication.

    inv-17: BALVERSA — listed indications

    Covered when ALL of the following are met for BALVERSA

    BALVERSA coverage criteria: 1) Diagnosis consistent with the listed FDA‑approved indication(s) (eg, unresectable or metastatic urothelial carcinoma with confirmed FGFR3 alteration); 2) Prior authorization is requested for an FDA‑approved indication; 3) Progression on or after at least one line of prior systemic therapy where specified.

    PA indicator: All FDA‑Approved Indications; confirm FGFR3 alteration where applicable.

    inv-18: RUFINAMIDE — listed indications

    Covered when ALL of the following are met for RUFINAMIDE

    RUFINAMIDE coverage criteria: 1) Diagnosis of the listed FDA‑approved indication (eg, locally advanced or metastatic urothelial carcinoma where applicable); 2) Confirmed FGFR3 genetic alteration where required; 3) Progression on or after at least one line of prior systemic therapy; 4) Prior authorization is requested.

    PA indicator: All FDA‑Approved Indications.

    inv-19: Initial/General Authorization Criteria (Seizure)

    Covered when ALL of the following are met

    Seizure indication: 1) Patient has inadequate seizure control despite treatment with at least ONE anti‑epileptic drug; 2) Prior authorization is requested for the FDA‑approved indication.at least 1 prior AED

    Coverage duration: Plan Year.

    inv-20: Initial/General Authorization Criteria (Lupus Nephritis / SLE)

    Covered when ALL of the following are met

    Lupus nephritis / SLE criteria: 1) Diagnosis of lupus nephritis or systemic lupus erythematosus with current active disease; 2) Patient has previous treatment with at least TWO of: corticosteroids, antimalarials, or immunosuppressives; 3) Patient will continue concomitant standard treatment with at least ONE of the listed classes; 4) Prior authorization is requested.at least 2 prior agents; at least 1 concomitant agent

    Coverage duration: Plan Year.

    inv-21: BESREMI Initial Therapy

    Covered when ALL of the following are met

    BESREMI initial: 1) Diagnosis of polycythemia vera; 2) Inadequate response to or intolerance of hydroxyurea; 3) Initial coverage duration: 6 months; 4) Prior authorization is requested.

    Reauthorization: Plan Year.

    inv-22: BOSULIF Therapy

    Covered when ALL of the following are met

    BOSULIF initial: 1) Diagnosis of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with disease phase specified; 2) For chronic‑phase CML, prior failure or intolerance to imatinib is documented; 3) Prior authorization is requested.

    Coverage duration: Plan Year.

    inv-23: Braftovi / Mektovi indications

    Covered when ALL of the following are met

    Braftovi / Mektovi indications: 1) Diagnosis of BRAF V600E or V600K mutation‑positive disease where applicable (eg, unresectable/metastatic melanoma); 2) Intended use in the specified combination regimen (eg, encorafenib + binimetinib for melanoma or NSCLC; encorafenib + cetuximab for CRC); 3) Prior authorization is requested.

    Mutation confirmation and intended combination therapy must be documented.

    inv-24: Brukinsa indications and prior therapy requirements

    Covered when ALL of the following are met

    Brukinsa indications: 1) Diagnosis of one of the covered hematologic malignancies (MCL, MZL, Waldenstrom macroglobulinemia, CLL/SLL, or relapsed/refractory FL); 2) Prior therapy requirements by indication are met: for MCL ≥1 prior therapy; for MZL prior anti‑CD20 regimen; for FL ≥2 prior lines and intended use with obinutuzumab; 3) Prior authorization is requested.

    Document prior therapy history per indication.

    inv-25: CABLIVI Coverage Criteria

    Covered when ALL of the following are met

    CABLIVI initial authorization: 1) Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP); 2) CABLIVI was started inpatient in combination with plasma exchange; 3) Initial approval duration per policy limits (3 months) and maximum 58 days following last day of plasma exchange; 4) Prior authorization is requested.

    Reauthorization requires evidence of persistent underlying disease and clinical response.

    inv-26: CABOMETYX Coverage Criteria

    Covered when ALL of the following are met per indication

    CABOMETYX HCC: Hepatocellular carcinoma: diagnosis of HCC AND previous use of sorafenib; prior authorization is requested.

    Per required medical information.

    CABOMETYX advanced RCC: Advanced renal cell carcinoma: diagnosis documented; prior authorization is requested.

    Per required medical information.

    CABOMETYX DTC: Differentiated thyroid cancer: locally advanced or metastatic DTC with progression following prior VEGFR‑targeted therapy and radioactive iodine‑refractory or ineligible status; prior authorization is requested.

    Per required medical information.

    CABOMETYX pNET: Previously treated, unresectable, locally advanced or metastatic well‑differentiated pancreatic neuroendocrine tumor with prior failure of everolimus or sunitinib; prior authorization is requested.

    inv-27: Cancer indications requiring prior therapies

    Covered when ALL of the following are met for the listed oncology indications

    Oncology indications group: Member has one of the listed diagnoses (HCC with prior sorafenib; advanced RCC; DTC with progression after VEGFR‑targeted therapy and RAI‑refractory or ineligible; previously treated unresectable well‑differentiated pNET with prior everolimus/sunitinib failure; previously treated unresectable well‑differentiated epNET).

    Each sub‑indication may require specific prior therapy as listed.

    inv-28: Medullary thyroid cancer

    Covered when ALL of the following are met for medullary thyroid cancer

    Medullary thyroid cancer: 1) Diagnosis of symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic; 2) Prior authorization is requested.

    Document symptomatic or progressive disease as required.

    inv-29: Drug-specific required information

    Coverage and required information for specific drugs

    carglumic acid initial: 1) Diagnosis of hyperammonemia due to N‑acetylglutamate synthase deficiency; 2) Prior authorization is requested.

    Per required medical information (chunk 254).

    sapropterin initial: 1) Diagnosis of hyperphenylalaninemia due to BH4‑responsive phenylketonuria; 2) Prior authorization is requested.

    Per required medical information (chunk 254).

    CHOLBAM initial: 1) Abnormal urinary bile acids analysis by FAB‑MS and neurologic exam documented for initial approval; 2) Prior authorization is requested.

    Per required medical information (chunk 264).

    CHOLBAM reauthorization: 1) Documentation of improvement in ALT/AST, bilirubin, and/or weight for reauthorization; 2) Prior authorization is requested.

    Coverage is excluded for members with hypersensitivity to Actimmune or E. coli–derived products. This is an explicit exclusion for Actimmune and must be documented prior to authorization or the request will be denied.

    No explicit exclusion criteria are listed for the medications in this section. Requests should be evaluated against the stated coverage criteria and required documentation rather than drug-specific exclusions.

    No explicit exclusion criteria are listed for the medications in this segment. Absent specified exclusions, standard contraindications and documented clinical rationale should guide coverage decisions.

    The patient must have none of the following health conditions or concerns: history of significant hepatic disease and alcohol abuse. Presence of either condition is listed as an exclusion and will preclude coverage.

    Initial Therapy / Authorization Requirements

    No explicit exclusion criteria or off‑label uses are listed for the medications in this section. Off‑label use is marked as N/A, so coverage determinations rely on the documented FDA‑approved indications and required supporting information.

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization required (Actimmune, Akeega)

    Prior authorization is required for all FDA‑approved indications for Actimmune and Akeega; submit a PA request before dispensing.

    Prior Authorization

    Alecensa prior authorization

    Alecensa requires prior authorization for all FDA‑approved indications; include documentation confirming ALK‑positive NSCLC when applicable.

    Prior Authorization

    Radicava ORS prior authorization

    Radicava ORS requires prior authorization for all FDA‑approved indications; provide documentation of ALS per the revised El Escorial criteria.

    Key Numeric & Diagnostic Thresholds

    inv-49: Serum testosterone — threshold for testosterone-related coverage
    Serum testosterone thresholdSerum testosterone < 300 ng/dL
    Measurement requirementTwo separate serum testosterone levels drawn on different dates
    Associated documentationDocumentation of at least one clinical symptom (malaise, fatigue, lethargy, muscle loss, depression, or decreased libido)
    inv-50: Serum testosterone — duplicate threshold entry (two separate measurements <300 ng/dL)
    Repeat serum testosterone thresholdSerum testosterone < 300 ng/dL on a second measurement
    TimingMeasurements must be drawn on different dates

    Step Therapy & Required Prior Trials

    Coverage requirementDetails
    Documentation of contraindication, intolerance, or failure of Lynparza
    Required prior to coverage of Akeega for deleterious or suspected deleterious BRCA‑mutated metastatic castration‑resistant prostate cancer
    Coverage requirementDetails
    Documented attempt or contraindication to Alecensa
    Patient must have failed, be intolerant of, or have a contraindication to Alecensa prior to authorization of ALUNBRIG for metastatic ALK‑positive NSCLC
    Coverage requirementDetails
    Previous trial on at least one listed agent
    Document prior trial on at least one of: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone; for MDD or schizophrenia additionally document a prior trial on Rexulti
    Coverage requirementDetails
    Prior trial of listed lipid‑lowering therapies
    Patient must have untreated fasting LDL >500 mg/dL and triglycerides <300 mg/dL, plus failed or currently taking at least one of atorvastatin, rosuvastatin, or simvastatin (or documented statin intolerance) and a prior trial of Repatha or Praluent
    Coverage requirementDetails
    Documented failure of prior therapies
    For ADBRY/CIBINQO in moderate to severe atopic dermatitis: documented failure of two of the following is required — topical corticosteroid; topical calcineurin inhibitor; phototherapy; oral immunomodulator (azathioprine, cyclosporine, or mycophenolate); or topical PDE‑4 (Eucrisa)
    Coverage requirementDetails
    Trial and failure/intolerance/contraindication to Rozlytrek
    Required prior to authorization of AUGTYRO for locally advanced or metastatic ROS1‑positive NSCLC or NTRK gene fusion‑positive solid tumors
    Coverage requirementDetails
    Prior treatment with Mekinist or documented rationale why Mekinist is inappropriate
    Required for Avmapki Fakzynja co‑pack (recurrent KRAS‑mutated, low‑grade serous ovarian cancer); if Mekinist was not used provide medical rationale explaining why it would be inappropriate
    Coverage requirementDetails
    Prior systemic therapy
    For the urothelial carcinoma indication, progression on or after at least one line of prior systemic therapy is required before coverage
    Coverage requirementDetails
    Document prior trials as listed
    Provider must document prior adequate trials: e.g., for seizure control at least one AED trial; for lupus nephritis/SLE prior treatment with at least two agents (corticosteroids, antimalarials, or immunosuppressives) and plan to continue concomitant therapy
    Coverage requirementDetails
    Document prior therapy failure/intolerance
    Examples: BESREMI requires inadequate response or intolerance to hydroxyurea; BOSULIF for CML chronic phase requires prior failure or intolerance to imatinib — documentation of these failures/intolerances is required
    Coverage requirementDetails
    Prior therapies required for certain indications
    For Brukinsa, document prior lines/types of therapy per indication (e.g., ≥1 prior therapy for MCL; prior anti‑CD20 regimen for MZL; ≥2 lines for FL when used with obinutuzumab)
    Coverage requirementDetails
    No step therapy specified
    No step therapy requirements are specified in this section

    Reauthorization / Continuation Requirements

    Site-of-Care Requirements

    Billing Rule

    CABlivi site‑of‑care requirement

    Initial CABLIVI therapy must be started inpatient in combination with plasma exchange; ensure site‑of‑care and inpatient initiation are documented.

    • CABLIVI must be started inpatient and used with plasma exchange for initial authorization

    Background & Scope Notes

    Background material beyond required diagnoses is not provided in this section. The document lists required diagnoses for each medication: for example, Alecensa is specified for ALK‑positive non‑small cell lung cancer, and Radicava ORS is listed for amyotrophic lateral sclerosis defined by the revised El Escorial criteria.

    Definitions and Terms

    inv-143: Chronic granulomatous disease — definition used for Actimmune
    DefinitionChronic granulomatous disease (CGD) — listed as a required diagnosis for Actimmune
    Authorization contextDocumentation of CGD is required for Actimmune initial authorization
    Exclusion noteHypersensitivity to Actimmune or E. coli derived products is an exclusion (see exclusions)
    inv-144: Severe malignant osteopetrosis — definition used for Actimmune
    DefinitionSevere malignant osteopetrosis — listed as a required diagnosis for Actimmune
    Authorization contextDocumentation of severe malignant osteopetrosis is required for Actimmune initial authorization

    Policy Revision History

    2025-11-01policy_reviewLatest

    Document last reviewed and updated (multiple pages show 'LAST UPDATED 11/2025').

    Policy Summary
    PayerSelectHealth
    PolicyCoverage criteria for Actimmune and Akeega (and related drug entries)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewNov 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for all FDA‑approved indications and provide required supporting documentation (e.g., diagnoses, prior therapy trials, two separate testosterone levels when applicable).
    SourceLink
    On This Page
    Coverage Criteria by MedicationInitial Therapy / Authorization RequirementsProvider Actions, Prior Authorization & DocumentationKey Numeric & Diagnostic ThresholdsStep Therapy & Required Prior TrialsReauthorization / Continuation RequirementsSite-of-Care RequirementsBackground & Scope NotesDefinitions and TermsPolicy Revision History

    Per required medical information.

    CABOMETYX epNET: Previously treated, unresectable, locally advanced or metastatic well‑differentiated extra‑pancreatic neuroendocrine tumor; prior authorization is requested.

    Per required medical information.

    Per required medical information (chunk 264).

    Coverage duration: Plan Year for initial and reauthorization unless specified otherwise.

    Per policy (chunk 257).

    Prior Authorization

    ALUNBRIG prior authorization and prerequisite

    Prior authorization is required for ALUNBRIG for ALK‑positive metastatic NSCLC; the patient must have failed, be intolerant to, or have a contraindication to Alecensa.

    Prior Authorization

    Topical testosterone prior authorization & lab/symptom requirements

    Prior authorization is required for the specified topical testosterone products for FDA‑approved indications; include two separate serum testosterone measurements and symptom documentation.

    • Two separate testosterone levels on different dates showing serum testosterone < 300 ng/dL
    • Documentation of at least one symptom (malaise, fatigue, lethargy, muscle loss, depression, or decreased libido)
    Prior Authorization

    PA required for listed psychotropic agents

    Prior authorization applies to the listed psychotropic medications; provide required prior‑trial documentation as specified elsewhere in the policy.

    Prior Authorization

    JUXTAPID prior authorization

    JUXTAPID is subject to prior authorization per this segment; submit PA documentation as required.

    Billing Rule

    Authorization duration and reauthorization rules

    Initial authorizations are generally time‑limited to 6 months; reauthorization is typically for the Plan Year and NPC indications require fSARA stability or improvement for reauthorization.

    • Initial authorization duration: 6 months
    • Reauthorization duration: Plan Year
    • NPC reauthorization requires fSARA score remained stable or improved
    Prior Authorization

    PA required for listed medications (general)

    Prior authorization is required for all FDA‑approved indications for the listed medications in this section; obtain PA before therapy initiation.

    Prior Authorization

    AUGTYRO prior authorization and required prior therapy documentation

    Prior authorization is required for AUGTYRO for all FDA‑approved indications and requires documentation of diagnosis and contraindication/intolerance/failure of Rozlytrek.

    • Document diagnosis (ROS1‑positive NSCLC or NTRK fusion‑positive solid tumor)
    • Document contraindication, intolerance, or failure of Rozlytrek
    Prior Authorization

    AUSTEDO prior authorization and required diagnosis

    Prior authorization is required for AUSTEDO (including XR and titration packs) for all FDA‑approved indications; include the documented diagnosis (chorea of Huntington disease or tardive dyskinesia).

    • Document diagnosis of chorea associated with Huntington's disease OR tardive dyskinesia
    Prior Authorization

    Prior authorization required (both listed medications)

    Both of the listed medications in this segment require prior authorization for all FDA‑approved indications; submit PA requests accordingly.

    Prior Authorization

    BALVERSA and RUFINAMIDE prior authorization

    Prior authorization is required for BALVERSA and RUFINAMIDE for their listed indications; PA applies to all FDA‑approved indications for each drug.

    Prior Authorization

    BENLYSTA prior authorization

    Prior authorization is required for BENLYSTA for all FDA‑approved indications; obtain PA and document required clinical information per indication.

    Prior Authorization

    BESREMI prior authorization and required prior therapy

    Prior authorization is required for BESREMI for all FDA‑approved indications; include documentation of diagnosis and prior hydroxyurea intolerance or inadequate response where applicable.

    • Document diagnosis of polycythemia vera
    • Document inadequate response or intolerance to hydroxyurea
    Prior Authorization

    PA required for BESREMI and BOSULIF

    Prior authorization is required for BESREMI and BOSULIF for all FDA‑approved indications as listed; follow PA submission requirements for each.

    Billing Rule

    Coverage duration for BESREMI and BOSULIF

    Initial authorization durations: BESREMI initial approval is 6 months with reauthorization for the Plan Year; BOSULIF authorization duration is Plan Year.

    • BESREMI initial: 6 months; reauthorization: Plan Year
    • BOSULIF authorization duration: Plan Year
    Prior Authorization

    Prior authorization required (listed medications)

    Prior authorization applies for all FDA‑approved indications for the medications listed in this section; submit complete documentation with the PA request.

    Prior Authorization

    PA required for listed medications (general)

    Prior authorization is required for the listed medications; PA indication is All FDA‑Approved Indications—obtain PA before treatment.

    Billing Rule

    CABLIVI authorization duration limits

    CABLIVI approvals are time‑limited: initial coverage is 3 months and a maximum of 58 days following the last day of plasma exchange applies; ensure PA and time‑limit documentation are clear.

    • Initial coverage duration: 3 months
    • Maximum of 58 days following last day of plasma exchange
    Prior Authorization

    Prior authorization indicated (listed drugs)

    Prior authorization is indicated for the listed medications and the PA indicator denotes coverage for all FDA‑approved indications; submit PA per policy.

    Prior Authorization

    PA required for CHOLBAM and COMETRIQ

    Prior authorization is required for CHOLBAM and COMETRIQ and both list the PA indication as 'All FDA‑Approved Indications'; include required documentation with the PA.

    Step Therapy

    Akeega step therapy requirement (Lynparza)

    For Akeega, document contraindication, intolerance, or failure of Lynparza before requesting coverage; include evidence of the prior Lynparza trial or contraindication.

    • Provide documentation of contraindication, intolerance, or treatment failure with Lynparza
    Note

    Step therapy: no other requirements specified

    No additional step therapy criteria are specified in this section beyond those explicitly listed for individual drugs.

    Step Therapy

    ALUNBRIG step therapy: Alecensa trial required

    Before ALUNBRIG will be authorized, document failure, intolerance, or contraindication to Alecensa; include supporting clinical notes or prior therapy records.

    • Document attempt with Alecensa and reason for discontinuation (failure, intolerance, or contraindication)
    Step Therapy

    Prior trial requirement for listed psychiatric agents

    For the listed psychiatric medications, provide documentation of a prior trial on at least one specified antipsychotic; for MDD or schizophrenia, a prior trial on Rexulti is required when indicated.

    • Prior trial on at least one of: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone
    • For MDD or Schizophrenia, prior trial on Rexulti
    Step Therapy

    Prior lipid‑lowering therapy required

    For severe hypercholesterolemia indications, document prior trial of at least one high/moderate‑intensity statin (atorvastatin, rosuvastatin, or simvastatin) and prior trial of Repatha or Praluent as specified.

    • Prior trial of atorvastatin, rosuvastatin, or simvastatin OR documented statin intolerance
    • Prior trial of Repatha OR Praluent
    Step Therapy

    Prior therapy requirement for atopic dermatitis agents

    For ADBRY/CIBINQO, document failure of two prior therapies (topical corticosteroid, topical calcineurin inhibitor, phototherapy, oral immunomodulator, or topical PDE‑4) before authorization.

    • Failure of two of: topical corticosteroid; topical calcineurin inhibitor; phototherapy; oral immunomodulator (azathioprine, cyclosporine, mycophenolate); topical PDE‑4 (Eucrisa)
    Step Therapy

    NPC prior therapy and eligibility requirements

    For the NPC indication after miglustat failure, document prior miglustat therapy of at least 3 months and other required genetic, weight, neurologic, ambulatory, and functional score criteria.

    • ≥3 months of miglustat therapy with documented failure
    • Weight ≥ 15 kg; genetic confirmation or alternative testing; neurologic symptoms and ambulatory status; SARA and HPT‑D criteria
    Step Therapy

    Avmapki Fakzynja step requirement: Mekinist

    For the Avmapki Fakzynja co‑pack, prior treatment with Mekinist is required or provide a documented medical rationale explaining why Mekinist is inappropriate.

    • Document prior Mekinist treatment OR provide rationale why Mekinist is inappropriate
    Step Therapy

    Prior systemic therapy required (urothelial carcinoma)

    For urothelial carcinoma indications, document progression on or after at least one line of prior systemic therapy before coverage is granted.

    Documentation Required

    Provider must document prior adequate trials

    Providers must document prior adequate trials: for seizure indications at least one anti‑epileptic drug trial; for lupus nephritis/SLE at least two prior agents and plan to continue concomitant therapy.

    • Seizure: documentation of inadequate control despite ≥1 AED
    • Lupus nephritis/SLE: prior treatment with ≥2 agents and plan to continue concomitant therapy with ≥1 agent
    Step Therapy

    Required prior therapy for BESREMI and BOSULIF

    For BESREMI, document prior intolerance or inadequate response to hydroxyurea; for BOSULIF, document prior failure or intolerance to imatinib for CML in chronic phase.

    • BESREMI: prior hydroxyurea intolerance or inadequate response
    • BOSULIF: prior imatinib failure or intolerance (chronic phase CML)
    Step Therapy

    Step/prior therapy requirements for Brukinsa

    For Brukinsa, document prior lines or types of therapy required by indication (e.g., ≥1 prior therapy for MCL; prior anti‑CD20 regimen for MZL; ≥2 prior lines for FL).

    • MCL: ≥1 prior therapy
    • MZL: prior anti‑CD20–based regimen
    • FL: ≥2 prior lines and will be used with obinutuzumab
    Note

    Prescriber restriction: none specified

    No prescriber restrictions are specified in these sections; prescriptions may be written by any appropriate provider meeting clinical standards.

    Documentation Required

    Required medical information: Actimmune and Akeega

    Required documentation for Actimmune includes diagnosis of chronic granulomatous disease or severe malignant osteopetrosis; for Akeega include diagnosis of BRCAm mCRPC and documentation of Lynparza contraindication/intolerance/failure.

    • Actimmune: document diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis
    • Akeega: document deleterious or suspected deleterious BRCA‑mutated mCRPC and prior Lynparza contraindication/intolerance/failure
    Documentation Required

    Alecensa required documentation (ALK positivity)

    For Alecensa, include documentation confirming ALK‑positive NSCLC (e.g., ALK test results) with the PA submission.

    • Provide test results confirming ALK positivity
    Documentation Required

    Radicava ORS required diagnostic documentation

    For Radicava ORS, provide documentation that the patient meets the ALS diagnosis per the revised El Escorial criteria when requesting PA.

    • Document ALS diagnosis as defined by the revised El Escorial criteria
    Documentation Required

    ALUNBRIG required medical information

    For ALUNBRIG, document metastatic ALK‑positive NSCLC and the patient’s failure, intolerance, or contraindication to Alecensa when submitting PA.

    • Document metastatic NSCLC with ALK‑positive tumor
    • Document failure/intolerance/contraindication to Alecensa
    Documentation Required

    Testosterone lab and symptom documentation required

    For testosterone‑related therapy, provide two separate serum testosterone measurements on different dates showing <300 ng/dL and documentation of at least one clinical symptom.

    • Two separate serum testosterone levels on different dates < 300 ng/dL
    • Documentation of at least one symptom (malaise, fatigue, lethargy, muscle loss, depression, decreased libido)
    Documentation Required

    Documentation required for listed psychiatric medications

    For the listed psychiatric medications, provide documentation of prior trial(s) on at least one of the specified antipsychotic agents; for MDD or schizophrenia, document a prior trial on Rexulti where applicable.

    • Document prior trial on one of: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone
    • For MDD or Schizophrenia, document prior trial on Rexulti
    Documentation Required

    Required medical information for severe hypercholesterolemia

    Provide documentation of untreated fasting LDL >500 mg/dL with triglycerides <300 mg/dL and supporting genetic/family/xanthoma evidence, plus prior trials of statin therapy and Repatha or Praluent where required.

    • Untreated fasting LDL > 500 mg/dL and TG < 300 mg/dL
    • Genetic or family history evidence for homozygous familial hypercholesterolemia or xanthomas before age 10
    • Prior trial of atorvastatin, rosuvastatin, or simvastatin OR documented statin intolerance
    • Prior trial of Repatha OR Praluent
    Documentation Required

    Required diagnostic information for ARCALYST and similar agents

    Provide diagnosis documentation supporting one of the listed indications (for example, cryopyrin‑associated periodic syndrome, recurrent pericarditis, or DIRA for ARCALYST) when requesting PA.

    • Document diagnosis consistent with the requested indication
    Documentation Required

    AUGTYRO required documentation

    For AUGTYRO, include documented diagnosis (ROS1‑positive NSCLC or NTRK fusion‑positive solid tumor) and evidence of contraindication, intolerance, or failure of Rozlytrek with the PA.

    • Diagnosis documentation
    • Rozlytrek contraindication/intolerance/failure documentation
    Documentation Required

    Avmapki Fakzynja required documentation and reauthorization evidence

    For Avmapki Fakzynja co‑pack, provide diagnosis, prior platinum‑based therapy, ECOG 0–1 performance status, prior Mekinist treatment (or rationale), and reauthorization evidence of no disease progression per RECIST v1.1 when applicable.

    • Diagnosis of recurrent KRAS‑mutated, recurrent low‑grade serous ovarian cancer
    • Prior platinum‑based therapy
    • ECOG performance status 0 or 1
    • Prior Mekinist treatment or documented rationale why inappropriate
    • Reauthorization: documentation showing no disease progression (RECIST v1.1 ≥20% increase = progression)
    Documentation Required

    Ayvakit required diagnosis documentation

    For Ayvakit, include documentation of the specific diagnosed indication (PDGFRA exon 18 mutation–positive GIST including D842V, Advanced Systemic Mastocytosis, or Indolent Systemic Mastocytosis).

    • Documented diagnosis of one of the covered indications (PDGFRA exon 18 mutation‑positive GIST including D842V; AdvSM; Indolent SM)
    Documentation Required

    Required molecular confirmation and prior therapy documentation

    Document diagnosis and molecular confirmation where specified (e.g., PDGFRA exon 18 mutation for GIST; FGFR3 alteration for urothelial carcinoma) and prior treatment history showing progression after at least one systemic therapy when required.

    • Provide molecular confirmation where required
    • Document prior therapy history and progression as specified
    Documentation Required

    Seizure documentation requirement

    Document that the patient has inadequate seizure control despite treatment with at least one anti‑epileptic drug when requesting coverage for seizure indications.

    • Evidence of inadequate seizure control despite ≥1 AED trial
    Documentation Required

    Lupus nephritis / SLE documentation requirements

    For lupus nephritis/SLE indications, document diagnosis, evidence of active disease, prior treatment with at least two listed agents, and plan to continue concomitant standard treatment with at least one agent.

    • Diagnosis of lupus nephritis or SLE with current active disease
    • Prior treatment with ≥2 of corticosteroids, antimalarials, immunosuppressives
    • Plan to continue concomitant standard treatment with ≥1 agent
    Documentation Required

    BESREMI and BOSULIF documentation requirements

    For BESREMI, document diagnosis of polycythemia vera and evidence of inadequate response or intolerance to hydroxyurea; for BOSULIF, document Ph+ CML diagnosis and prior imatinib failure/intolerance where applicable.

    Documentation Required

    CABLIVI documentation and inpatient start requirement

    For CABLIVI initial authorization, document diagnosis of acquired TTP and that CABLIVI was started inpatient in combination with plasma exchange; include reauthorization evidence of persistent disease and clinical response.

    • Initial: diagnosis of aTTP and inpatient start with plasma exchange
    • Reauth: evidence of persistent disease (e.g., suppressed ADAMTS13) and clinical response (increased platelets, reduced neurologic symptoms, improved organ markers)
    Documentation Required

    CABOMETYX required clinical documentation

    For CABOMETYX and other oncology agents, include documentation of the specific FDA‑approved carcinoma diagnosis and prior therapies as applicable (e.g., prior sorafenib for HCC).

    • Document specific carcinoma diagnosis
    • Provide prior therapy history as required (e.g., prior sorafenib for HCC)
    Documentation Required

    CHOLBAM documentation requirements

    For CHOLBAM initial authorization provide abnormal urinary bile acids analysis by FAB‑MS and neurologic exam; for reauthorization provide evidence of improvement in liver tests and/or weight.

    • Initial: abnormal urinary bile acids by FAB‑MS and neurologic exam findings
    • Reauth: improvement in ALT/AST, bilirubin, and/or weight
    Denial Risk

    Actimmune hypersensitivity exclusion (denial risk)

    Coverage will be excluded for members with hypersensitivity to Actimmune or E. coli‑derived products; do not submit PA for such members.

    Denial Risk

    Alecensa denial risk: missing ALK documentation

    Lack of documentation confirming ALK‑positive NSCLC may trigger denial for Alecensa; include ALK test results with the PA.

    Denial Risk

    Radicava ORS denial risk: missing ALS documentation

    Lack of documentation confirming ALS diagnosis per the revised El Escorial criteria may trigger denial for Radicava ORS; include the diagnostic criteria evidence.

    Denial Risk

    ALUNBRIG denial risk: missing diagnosis or Alecensa trial

    Coverage may be denied for ALUNBRIG if the diagnosis is not metastatic ALK‑positive NSCLC or if failure/intolerance/contraindication to Alecensa is not documented.

    Denial Risk

    Testosterone documentation denial risk

    Coverage may be denied for testosterone therapy if two separate testosterone measurements on different dates showing serum testosterone <300 ng/dL and required signs or symptoms are not provided.

    • Two separate testosterone levels on different dates < 300 ng/dL are required
    • At least one qualifying symptom must be documented
    Denial Risk

    Testosterone lab requirement — denial risk

    Failure to provide two separate testosterone levels on different dates with serum testosterone below 300 ng/dL may trigger denial for testosterone‑related indications.

    Denial Risk

    Prior trial documentation denial risk (psychiatric agents)

    Lack of documented prior trial on at least one of the listed antipsychotics may trigger denial for the indicated psychiatric medications; ensure prior‑trial records are included.

    • Document prior trial on an appropriate antipsychotic (listed in policy)
    Denial Risk

    Exclusion criteria and combination exclusion (denial risk)

    Requests will be excluded if the patient has significant hepatic disease or alcohol abuse; use of AQNEURSA in combination with Miplyffa is excluded—verify exclusions before submitting PA.

    • History of significant hepatic disease or alcohol abuse excludes coverage
    • AQNEURSA used in combination with Miplyffa is excluded
    Denial Risk

    Combination therapy exclusions (denial risk)

    Coverage is excluded when ARCALYST is used in combination with a TNF‑inhibitor, and ADBRY/CIBINQO are excluded when used with another biologic; document concurrent therapies.

    • ARCALYST + TNF‑inhibitor: excluded
    • ADBRY/CIBINQO + another biologic (e.g., Dupixent, Xolair): excluded
    Denial Risk

    Documentation deficiencies may trigger denial (Avmapki Fakzynja)

    Lack of required documentation such as prior platinum‑based therapy, ECOG 0–1 status, or evidence regarding Mekinist may trigger denial for Avmapki Fakzynja; include these items when applicable.

    • Document prior platinum‑based therapy and ECOG performance status
    • Document prior Mekinist treatment or rationale if not used
    Denial Risk

    Missing indication or molecular documentation (denial risk)

    For Ayvakit and similar agents, absence of documentation of the specific diagnosed indication or requisite molecular criteria may lead to denial; include mutation confirmation when required.

    • Provide PDGFRA exon 18 mutation confirmation for GIST where required
    • Document diagnosis of AdvSM or Indolent SM as applicable
    Denial Risk

    Genetic alteration and prior therapy denial risk (urothelial carcinoma)

    Absence of confirmed FGFR3 genetic alteration or lack of progression after prior systemic therapy may trigger denial for the urothelial carcinoma indication—include genetic and prior‑therapy evidence.

    • Confirm FGFR3 genetic alteration
    • Document progression after ≥1 line of systemic therapy
    Denial Risk

    Seizure indication denial risk: missing AED trial documentation

    Lack of documentation showing inadequate seizure control despite treatment with at least one anti‑epileptic drug may trigger denial for seizure indications.

    Denial Risk

    Lupus nephritis / SLE denial risk: missing prior/concomitant therapy

    For lupus nephritis/SLE indications, failure to document prior treatment with at least two agents or lack of documentation of continued concomitant therapy may trigger denial.

    • Document prior treatment with ≥2 listed agent classes
    • Document plan to continue concomitant standard treatment with ≥1 agent
    Denial Risk

    Missing clinical justification (denial risk)

    Lack of required medical information (e.g., no documented diagnosis of polycythemia vera or no documentation of inadequate response/intolerance to hydroxyurea) may trigger denial for BESREMI or BOSULIF requests.

    Denial Risk

    Documentation and prior therapy gaps (denial risk)

    Lack of diagnostic confirmation (e.g., no BRAF V600E/V600K documentation) or absence of required prior therapies may cause denial for oncology agents; include mutation and prior‑therapy evidence.

    Denial Risk

    CABLIVI initial authorization denial risk

    For CABLIVI, lack of documented diagnosis of aTTP or absence of documentation that therapy was started inpatient with plasma exchange may trigger denial for initial authorization.

    Denial Risk

    CABOMETYX authorization denial risk

    For CABOMETYX, missing documentation of the specific FDA‑approved oncology diagnosis or prior therapy history (e.g., prior sorafenib for HCC) may trigger denial; include required prior‑therapy records.

    Denial Risk

    Missing required prior therapies or diagnoses (denial risk)

    Lack of required diagnosis or prior therapy (for example, no prior sorafenib for hepatocellular carcinoma or no prior VEGFR‑targeted therapy for DTC) may trigger denial; verify and document prior therapies.

    Denial Risk

    Medullary thyroid cancer documentation denial risk

    Absence of documented symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease may trigger denial for related requests.

    Denial Risk

    Missing required diagnosis (metabolic therapies) — denial risk

    Requests lacking documentation that carglumic acid is for hyperammonemia due to N‑acetylglutamate synthase deficiency or that sapropterin is for BH4‑responsive phenylketonuria may be denied.

    Denial Risk

    CHOLBAM lab/clinical documentation denial risk

    For CHOLBAM initial requests, absence of abnormal urinary bile acids by FAB‑MS and neurologic exam findings may trigger denial; for reauthorization, lack of improvement in ALT/AST, bilirubin, or weight may trigger denial.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Clinical corroborationAt least one related symptom must be documented (malaise, fatigue, lethargy, muscle loss, depression, decreased libido)
    inv-51: Untreated fasting LDL — threshold for severe hypercholesterolemia
    Untreated fasting LDL thresholdUntreated, fasting LDL cholesterol > 500 mg/dL
    Triglyceride requirementTriglycerides < 300 mg/dL
    Genetic/family criteriaDocumentation of mutations in both alleles OR parental hypercholesterolemia OR xanthomas before age 10
    inv-52: Triglycerides — threshold for severe hypercholesterolemia
    Triglycerides thresholdTriglycerides < 300 mg/dL
    ContextRequired together with untreated, fasting LDL > 500 mg/dL for HFH criteria
    Prior therapy notePrior trial of high/moderate-intensity statin and prior trial of Repatha or Praluent required
    inv-53: Patient weight (NPC indication) — minimum weight
    Minimum patient weight>= 15 kg
    ContextRequired for Niemann‑Pick disease type C (post-miglustat failure) indication
    Other NPC prerequisitesAlso requires genetic confirmation and ≥3 months miglustat failure documentation
    inv-54: SARA total score — eligibility score range
    SARA total score range>= 7 and <= 34
    UsageRequired as part of Niemann‑Pick disease type C eligibility (out of 40)
    Reauthorization criterionfSARA score must remain stable or improve for reauthorization
    inv-55: HPT-D (9-Hole Peg Test) dominant hand time — threshold range
    HPT-D (9-Hole Peg Test) dominant hand time>= 20 and <= 150 seconds
    RoleAcceptable HPT-D time is an alternative functional requirement alongside SARA gait subtest
    ContextMeasured as part of SCAFI/HPT-D performance for NPC eligibility
    inv-56: Body Surface Area (BSA) — atopic dermatitis threshold
    Body Surface Area (BSA) threshold>= 10 percent
    IndicationDefines moderate to severe atopic dermatitis for ADBRY/CIBINQO coverage
    Prior therapy requirementFailure of two specified prior therapies required in addition to BSA criterion
    inv-57: Disease progression threshold (RECIST v1.1) — reauthorization progression definition
    Disease progression (RECIST v1.1)>= 20% increase in the sum of the diameters of target lesions
    Use caseDefined threshold for reauthorization disease‑progression assessment (Avmapki Fakzynja reauth)
    Reference standardPer RECIST version 1.1 criteria
    Related requirementPrior authorization for an FDA‑approved indication must be obtained
    inv-145: BRCAm mCRPC — definition used in Akeega context
    DefinitionDeleterious or suspected deleterious BRCA‑mutated metastatic castration‑resistant prostate cancer (BRCAm mCRPC)
    Authorization contextRequired documented diagnosis for Akeega initial coverage
    Step requirementDocumentation of contraindication, intolerance, or failure of Lynparza required prior to coverage
    inv-146: ALK-positive — tumor biomarker definition
    DefinitionALK‑positive — tumors positive for anaplastic lymphoma kinase (ALK) rearrangement
    Authorization contextRequired to document ALK‑positive NSCLC for Alecensa and as prerequisite for ALUNBRIG (after Alecensa failure/intolerance/contraindication)
    EvidenceDiagnostic test results confirming ALK positivity should be provided
    inv-147: ALS (per revised El Escorial criteria) — diagnostic definition
    DefinitionAmyotrophic lateral sclerosis (ALS) — diagnosis as defined by the revised El Escorial criteria
    Authorization contextDocumentation of ALS per revised El Escorial criteria is required for Radicava ORS authorization
    SourcePolicy requires explicit documentation of this diagnostic standard
    inv-148: ALK-positive metastatic NSCLC — disease definition
    DefinitionALK‑positive metastatic NSCLC — non‑small cell lung cancer with ALK rearrangement
    Authorization contextRequired diagnosis for ALUNBRIG initial coverage (after Alecensa failure/intolerance/contraindication)
    DocumentationProvider must document metastatic NSCLC that is ALK‑positive
    inv-149: Low serum testosterone — definition requires two separate measurements
    DefinitionLow serum testosterone — two separate serum testosterone measurements on different dates demonstrating levels below 300 ng/dL
    Clinical requirementDocumentation of at least one symptom (malaise, fatigue, lethargy, muscle loss, depression, decreased libido) is required
    Measurement specificsEach level must be below 300 ng/dL
    inv-150: Low serum testosterone — duplicate definition entry
    Duplicate entry definitionSerum testosterone level below 300 ng/dL documented on two separate dates
    Authorization implicationFailure to provide two separate measurements may trigger denial
    Symptom documentationAt least one related clinical symptom must be documented
    inv-151: SARA score — definition and eligibility thresholds
    SARA score definitionScale for the Assessment and Rating of Ataxia (SARA); eligibility requires total score >=7 and <=34
    Associated functional requirementsMust also meet gait subtest range OR HPT‑D performance as specified
    Reauthorization notefSARA score must remain stable or improve for reauthorization
    inv-152: Genetic confirmation for NPC — definition of genetic test requirements
    Genetic confirmationDNA sequence analysis showing mutations in both alleles of NPC1 or NPC2 OR single allele mutation with positive filipin staining or elevated cholestane triol/oxysterols (>2x ULN)
    ContextRequired for genetic confirmation of Niemann‑Pick disease type C for AQNEURSA coverage
    Additional clinical requirementsAlso requires neurological symptoms, ambulatory status, weight >=15 kg, and failed ≥3 months of miglustat
    inv-153: Moderate to severe atopic dermatitis (AD) — definition used for ADBRY/CIBINQO
    DefinitionModerate to severe atopic dermatitis: involvement of >=10% body surface area
    Prior therapy requirementFailure of two therapies among topical corticosteroid, topical calcineurin inhibitor, phototherapy, oral immunomodulator, or topical PDE‑4 is required
    Reauthorization detailFor Adbry reauth, patients <100 kg who achieved clear/almost clear skin should have tried every‑4‑week dosing
    inv-154: AUGTYRO / AUSTEDO indications — documented diagnoses required
    Required diagnosesAUGTYRO: locally advanced or metastatic ROS1‑positive NSCLC OR NTRK gene fusion‑positive solid tumors; AUSTEDO: chorea associated with Huntington's disease OR tardive dyskinesia
    Step/prior therapyAUGTYRO requires contraindication/intolerance/failure of Rozlytrek before authorization
    DocumentationDocumented diagnosis is required for authorization
    inv-155: Disease progression (for reauthorization) — RECIST v1.1 definition
    Disease progression definition>= 20% increase in the sum of the diameters of target lesions (RECIST v1.1)
    UsageUsed to determine disease progression for reauthorization (Avmapki Fakzynja) and other oncology reauthorizations
    Source standardPer RECIST version 1.1 criteria
    inv-156: Advanced Systemic Mastocytosis (AdvSM) — definition
    Advanced Systemic Mastocytosis (AdvSM)Includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM‑AHN), and mast cell leukemia (MCL)
    Authorization contextAdvSM is a listed indication for Ayvakit/BALVERSA coverage
    DocumentationProvider must document the specific AdvSM subtype as applicable
    inv-157: PDGFRA exon 18 mutation — definition used for GIST indication
    PDGFRA exon 18 mutation definitionPlatelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V substitution
    Authorization contextRequired molecular confirmation for unresectable/metastatic GIST indication
    Documentation requirementProvider must document PDGFRA exon 18 mutation (including D842V) for Ayvakit/BALVERSA approval
    inv-158: concomitant standard treatment — definition placeholder
    Concomitant standard treatmentContinuation of at least one concomitant agent (corticosteroid, antimalarial, or immunosuppressive) is required for BENLYSTA in lupus nephritis/SLE
    ContextApplies to BENLYSTA continuation and authorization criteria
    Prior therapy requirementPrior treatment with at least two agents from listed classes is required for initial BENLYSTA authorization
    inv-159: hydroxyurea failure/intolerance — definition used for BESREMI
    Hydroxyurea failure/intoleranceInadequate response or intolerance to hydroxyurea
    Authorization contextRequired prior therapy failure for BESREMI initial coverage in polycythemia vera
    DocumentationProvider must document inadequate response or intolerance to hydroxyurea
    inv-160: imatinib failure/intolerance — definition used for BOSULIF
    Imatinib failure/intolerancePrevious failure or intolerance to imatinib
    Authorization contextRequired for BOSULIF in chronic phase Ph+ CML prior to approval
    DocumentationProvider must document imatinib failure or intolerance
    inv-161: BRAF mutation — BRAF V600E or V600K mutation-positive definition
    BRAF mutation definitionBRAF V600E or V600K mutation‑positive
    Authorization contextRequired diagnostic confirmation for Braftovi/Mektovi combinations
    DocumentationProvider must document mutation type and intended combination therapy
    inv-162: anti-CD20-based regimen — definition used for Brukinsa prior therapy requirement
    anti‑CD20‑based regimenPrior anti‑CD20–based regimen refers to therapies such as rituximab or similar agents
    Authorization contextRequired prior therapy for Brukinsa in marginal zone lymphoma (MZL)
    DocumentationProvider must document prior anti‑CD20 treatment
    inv-163: aTTP — acquired thrombotic thrombocytopenic purpura definition used for CABLIVI
    aTTP definitionAcquired thrombotic thrombocytopenic purpura (aTTP)
    Initial therapy requirementCABLIVI must be started inpatient in combination with plasma exchange
    Reauthorization criteriaPersistent disease (e.g., suppressed ADAMTS13) and demonstrated clinical response required
    inv-164: previous use of sorafenib — definition for CABOMETYX HCC indication
    Previous use of sorafenibExplicit prior treatment with sorafenib required for the hepatocellular carcinoma indication
    Authorization contextRequired prior therapy for CABOMETYX HCC indication
    DocumentationProvider must document prior sorafenib use
    inv-165: progression following prior VEGFR-targeted therapy — definition for DTC indication
    Progression following prior VEGFR‑targeted therapyDisease progression after prior therapy targeting VEGF receptors
    Authorization contextRequired for differentiated thyroid cancer (DTC) indication for CABOMETYX
    DocumentationProvider must document prior VEGFR‑targeted therapy and progression
    inv-166: symptomatic or progressive medullary thyroid cancer — definition used for CABOMETYX
    Symptomatic or progressive medullary thyroid cancerMedullary thyroid cancer that is symptomatic or showing progression and is unresectable locally advanced or metastatic
    Authorization contextRequired diagnosis for indicated medullary thyroid cancer coverage
    DocumentationProvider must document symptomatic or progressive, unresectable locally advanced or metastatic disease
    inv-167: Hyperammonemia due to N-acetylglutamate synthase deficiency — definition used for carglumic acid
    Hyperammonemia due to N-acetylglutamate synthase deficiencySpecific metabolic disorder required for carglumic acid use
    Authorization contextProvider must document hyperammonemia due to NAGS deficiency for carglumic acid
    RelevanceListed under required medical information for carglumic acid
    inv-168: BH4-responsive Phenylketonuria — definition used for sapropterin
    BH4‑responsive PhenylketonuriaPhenylketonuria subtype responsive to tetrahydrobiopterin (sapropterin) therapy
    Authorization contextRequired diagnosis for sapropterin approval
    DocumentationProvider must document BH4‑responsive hyperphenylalaninemia